BIOMAT Database Logo BIOMAT Database Logo

Effect of food on the bioavailability of pentopril, an angiotensin-converting-enzyme inhibitor, in healthy subjects. 1985

A Rakhit, and M E Hurley, and E Redalieu, and G Kochak, and V Tipnis, and J Coleman, and A Rommel

Pentopril (CGS 13945) was administered in 125-mg capsules to eight healthy men on two occasions according to a randomized schedule; on one occasion in the fasting state and on the other occasion immediately following the ingestion of a standardized meal. Unlike captopril, a prototype angiotensin-converting-enzyme inhibitor, there was no significant difference in the peak plasma concentration for either the drug or its active metabolite (CGS 13934) between the fasting and the fed states. There was also no appreciable change in the area under the plasma curve for the drug and its metabolite after administration of drug in the presence of food compared with a fasting state. There was, however, a lag time in drug absorption after ingestion of food, which resulted in a significant increase in peak time for the active metabolite in plasma. Food delays the body's absorption of the drug and hence the appearance of its active metabolite in plasma without any significant effect on the relative bioavailability. Because relative bioavailability is not affected in the presence of food, such a delay may not have any therapeutic importance on chronic administration.

UI MeSH Term Description Entries
D007211 Indoles Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008954 Models, Biological Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment. Biological Model,Biological Models,Model, Biological,Models, Biologic,Biologic Model,Biologic Models,Model, Biologic
D005502 Food Substances taken in by the body to provide nourishment. Foods
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000806 Angiotensin-Converting Enzyme Inhibitors A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. ACE Inhibitor,ACE Inhibitors,Angiotensin Converting Enzyme Inhibitor,Angiotensin I-Converting Enzyme Inhibitor,Angiotensin-Converting Enzyme Inhibitor,Kininase II Inhibitor,Kininase II Inhibitors,Angiotensin I-Converting Enzyme Inhibitors,Angiotensin-Converting Enzyme Antagonists,Antagonists, Angiotensin-Converting Enzyme,Antagonists, Kininase II,Inhibitors, ACE,Inhibitors, Angiotensin-Converting Enzyme,Inhibitors, Kininase II,Kininase II Antagonists,Angiotensin Converting Enzyme Antagonists,Angiotensin Converting Enzyme Inhibitors,Angiotensin I Converting Enzyme Inhibitor,Angiotensin I Converting Enzyme Inhibitors,Antagonists, Angiotensin Converting Enzyme,Enzyme Antagonists, Angiotensin-Converting,Enzyme Inhibitor, Angiotensin-Converting,Enzyme Inhibitors, Angiotensin-Converting,II Inhibitor, Kininase,Inhibitor, ACE,Inhibitor, Angiotensin-Converting Enzyme,Inhibitor, Kininase II,Inhibitors, Angiotensin Converting Enzyme
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities

Related Publications

A Rakhit, and M E Hurley, and E Redalieu, and G Kochak, and V Tipnis, and J Coleman, and A Rommel
Effects of food on the bioavailability of CGS 16617, an angiotensin-converting enzyme inhibitor, in healthy subjects.
September 1988, Journal of clinical pharmacology,
A Rakhit, and M E Hurley, and E Redalieu, and G Kochak, and V Tipnis, and J Coleman, and A Rommel
Effect of food on the bioavailability of lisinopril, a nonsulfhydryl angiotensin-converting enzyme inhibitor.
April 1986, Journal of pharmaceutical sciences,
A Rakhit, and M E Hurley, and E Redalieu, and G Kochak, and V Tipnis, and J Coleman, and A Rommel
Determination of pentopril, an angiotensin converting enzyme inhibitor, and its active metabolite in urine.
December 1985, Journal of chromatography,
A Rakhit, and M E Hurley, and E Redalieu, and G Kochak, and V Tipnis, and J Coleman, and A Rommel
[Effect of angiotensin converting enzyme genotype on endothelial function in healthy subjects].
February 2008, Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology,
A Rakhit, and M E Hurley, and E Redalieu, and G Kochak, and V Tipnis, and J Coleman, and A Rommel
Effect of captopril (an angiotensin-converting enzyme inhibitor) on intraocular pressure in healthy human volunteers.
January 1989, Journal of ocular pharmacology,
A Rakhit, and M E Hurley, and E Redalieu, and G Kochak, and V Tipnis, and J Coleman, and A Rommel
Effect of tepoxalin on renal function in healthy dogs receiving an angiotensin-converting enzyme inhibitor.
December 2005, Journal of veterinary pharmacology and therapeutics,
A Rakhit, and M E Hurley, and E Redalieu, and G Kochak, and V Tipnis, and J Coleman, and A Rommel
Effect of food on the oral bioavailability of the angiotensin receptor - neprilysin inhibitor sacubitril/valsartan (LCZ696) in healthy subjects
.
December 2016, International journal of clinical pharmacology and therapeutics,
A Rakhit, and M E Hurley, and E Redalieu, and G Kochak, and V Tipnis, and J Coleman, and A Rommel
Perindopril, a new angiotensin converting enzyme inhibitor--clinical pharmacological studies in healthy subjects.
January 1987, Clinical and experimental hypertension. Part A, Theory and practice,
A Rakhit, and M E Hurley, and E Redalieu, and G Kochak, and V Tipnis, and J Coleman, and A Rommel
Pharmacokinetics, safety, and pharmacologic effects of fosinopril sodium, an angiotensin-converting enzyme inhibitor in healthy subjects.
January 1991, Journal of clinical pharmacology,
A Rakhit, and M E Hurley, and E Redalieu, and G Kochak, and V Tipnis, and J Coleman, and A Rommel
Disposition of pentopril, a new orally active angiotensin-converting enzyme inhibitor, and its active metabolite in rats.
September 1985, Journal of pharmaceutical sciences,
Copied contents to your clipboard!